| 38.79 -7.46 (-16.13%) | 10-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 53.54 |
1-year : | 58.86 |
| Resists | First : | 45.84 |
Second : | 50.4 |
| Pivot price | 44.61 |
|||
| Supports | First : | 38.47 |
Second : | 32 |
| MAs | MA(5) : | 45.33 |
MA(20) : | 43.83 |
| MA(100) : | 35.51  |
MA(250) : | 30.6 |
|
| MACD | MACD : | 1.5 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 49.3 |
D(3) : | 63.7 |
| RSI | RSI(14): 40.7 |
|||
| 52-week | High : | 50.4 | Low : | 16.53 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LENZ ] has closed above bottom band by 8.3%. Bollinger Bands are 112.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 49.22 - 49.48 | 49.48 - 49.7 |
| Low: | 45.32 - 45.61 | 45.61 - 45.84 |
| Close: | 45.79 - 46.27 | 46.27 - 46.67 |
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Fri, 10 Oct 2025
When is the best time to exit LENZ Therapeutics Inc. - Market Movers & Verified Technical Signals - newser.com
Fri, 10 Oct 2025
Using portfolio simulators with LENZ Therapeutics Inc. included - Weekly Trend Report & AI Powered Market Entry Ideas - newser.com
Fri, 10 Oct 2025
Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch - Investing.com
Fri, 10 Oct 2025
Weiss Ratings Reiterates Sell (D-) Rating for LENZ Therapeutics (NASDAQ:LENZ) - MarketBeat
Wed, 08 Oct 2025
Lenz Therapeutics sells $80 million in common stock in block trade - Investing.com
Mon, 06 Oct 2025
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 3.9% - Here's Why - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 99.4 (%) |
| Shares Short | 5,020 (K) |
| Shares Short P.Month | 4,820 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.23 |
| Profit Margin | 0 % |
| Operating Margin | -337.2 % |
| Return on Assets (ttm) | -18.5 % |
| Return on Equity (ttm) | -26.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.17 |
| Sales Per Share | 0.17 |
| EBITDA (p.s.) | -2.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -23.8 |
| PEG Ratio | 0 |
| Price to Book value | 5.35 |
| Price to Sales | 221.25 |
| Price to Cash Flow | -23.43 |
| Dividend | 7.21 |
| Forward Dividend | 0 |
| Dividend Yield | 18.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|